Use of hR3 MAb and radiotherapy to treat patients with non small cells lung cancer (NSCLC) and brain metastasis.

Trial Profile

Use of hR3 MAb and radiotherapy to treat patients with non small cells lung cancer (NSCLC) and brain metastasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry.
    • 03 Nov 2008 Preliminary results have been presented at the 2008 EORTC-NCI-AACR annual meeting, according to a YM Biosciences media release.
    • 03 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top